****

**Kongressprogramm 2021** (Stand 15.3.2021)

|  |  |  |
| --- | --- | --- |
| 08.45 | Kongresseröffnung und Grusswort / Opening | Reto ZILLIG  Heidi TANNO |
| 08.50-09.35 | * Beneficial effects of Dry Needling quantified by ultrasonography, self-reports and physical measures | Jay SHAH MD  (USA) |
|  | Fragen aus dem Auditorium / Questions from the audience |  |
| 09.40-10.00 | Kaffeepause / Coffeebreak |  |
| 10.00-10.40 | * Adverse effects of dry-needling therapy: current status and future research | Aitor MARTIN PINTADO PhD, MSc, PT  (ESP) |
|  | Fragen aus dem Auditorium / Questions from the audience |  |
| 10.45-11.25 | * Outcome of dry-needling-therapy concerning spastic muscle associated pain and dysfunction | Sheng Li MD, PhD  (USA) |
|  | Fragen aus dem Auditorium / Questions from the audience |  |
| 11.30-12.10 | * New evidence on biopsy in MTrPs and there implication on the diagnosis of myofascial pain * Dry Needling under EMG-guidance | Orlando Mayoral PhD  (ESP) |
|  | Fragen aus dem Auditorium / Questions from the audience |  |
| 12.15-13.00 | Lunchbreak |  |
| 13.00-13.40 | * Effectiveness of dry needling for myofascial trigger points in musculoskeletal disorders: protocol for an overview of a systematic review * Effectiveness of Low-Level Laser Therapy Targeting Myofascial  Trigger Points: A Systematic Review and Meta-analysis | Marco BARBERO PhD  (SUI) |
|  | Fragen aus dem Auditorium / Questions from the audience |  |
| 13.45-14.25 | * Kritische Betrachtung der wissenschaftlichen Grundlagen von Triggerpunkten und deren Bezug zum Dry Needling | Prof.Dr.med.  Sigfried MENSE  (GER) |
|  | Fragen aus dem Auditorium / Questions from the audience |  |
| 14.30-14.45 | * Praxiserfahrungen mit DNT bei Patienten mit Spastik | Valentina Keller PT  (SUI) |
|  | Fragen aus dem Auditorium / Questions from the audience |  |
| 14.50-15.20 | * Ultraschall geführtes Dry Needling in Tabuzonen: Praxiserfahrungen | Alexander GÜRTLER PT  Stephan Bürgin Dr.med.  (SUI) |
|  | Fragen aus dem Auditorium / Questions from the audience |  |
| 15.25-15.55 | * Überblick zur Evidenzlage der DNT und deren Outcome in weiteren Diagnosebereichen und Therapieparametern | Reto Zillig PT  (SUI) |
| 15.55-16.00 | Kongressabschluss |  |